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RESEARCH ARTICLE
First trimester serum PAPP-A levels and the prediction of small-for-gestational age 
infants
İlk trimester serum PAPP-A düzeyleri ve gebelik yaşına göre küçük bebeklerin tahmin edilmesi
Nilgün Güdücü, Gökçenur Gönenç, Herman İşçi, Alin Başgül Yiğiter, İlkkan Dünder
İstanbul Bilim University, Europe Hospital, Department of Obstetrics and Gynecology, İstanbul, Turkey
ÖZET
Amaç: Bu çalışmanın amacı ilk trimester serum PAPP-
A (pregnancy aasociated plasma protein A) seviyelerinin 
gebelik yaşına göre küçük (GYK) bebekleri tahmin etme-
de kullanılabilirliğini tespit etmektir.
Gereç ve yöntem:  Geriye  dönük  olarak  hastanemizin 
gebe kayıtları incelendi ve ilk trimester Down sendromu 
tarama testlerinin sonuçları bulundu. PAPP-A seviyeleri 5. 
persentilin altında kalanlar GYK bebek olarak kabul edildi.
Bulgular:  Düşük  PAPP-A  seviyeleri  ile  GYK  bebekler 
arasında bir ilişki mevcuttur, testin duyarlılığı %3,5, özgül-
lüğü %90, pozitif kestirim değeri %1,6 ve negatif kestirim 
değeri %95tir.
Sonuç:  Testin  pozitif  kestirim  değerinin  düşük  olması 
nedeniyle GYK bebekleri tahmin etmek için kullanılması 
uygun değildir. 
Anahtar kelimeler:  gebelik  yaşına  göre  küçük  bebek, 
PAPP-A, gebelik
ABSTRACT
Objectives:  The  aim  of  this  study  was  to  detect  the 
predictive value of PAPP-A in small-for-gestational age 
(SGA) infants.
Materials and methods:  We  retrospectively  searched 
the patient charts of our hospital for first trimester Down 
syndrome screening test results. PAPP-A levels less than 
5th percentile were considered as predictive of SGA in-
fants.
Results: Low PAPP-A levels were associated with SGA 
infants,  sensitivity  was  3,5%,  specificity  90%,  positive 
predictive value 1,6% and negative predictive value 95%.
Conclusions: The low positive predictive value of PAPP-
A prevents it from being used as a screening test for the 
detection of SGA infants. J Clin Exp Invest 2012; 3(2): 
185-188
Key words:  Small  for  gestational  age,  PAPP-A,  preg-
nancy
INTRODUCTION
Early antenatal detection of pregnancies with small-
for-gestational-age fetuses is important to provide 
monitoring  for  the  prevention  of  complications.1,2 
Pregnancies at increased risk of developing small 
for gestational age (SGA) fetuses can be diagnosed 
by making additional use of tests formerly obtained 
for Down syndrome screening. First trimester serum 
screening for Down’s syndrome uses fetal nuchal 
translucency (NT) with free beta-human chorionic 
gonadotropin (free β-hCG) and pregnancy associ-
ated plasma protein A (PAPP-A). PAPP-A is a tro-
phoblast-derived metalloproteinase breaking down 
IGFBPs, degraded particles of IGFBPs bind IGFs 
and inhibits their interaction with cell surface recep-
tors.3 It is released into the fetal blood and then it 
passes from placenta to maternal blood, concen-
trations increase as the gestation progresses from 
10 to 13 weeks due to enlargement of the placen-
ta.4 The aim of our study was to search the role of 
PAPP-A as a screening test for the detection of SGA 
fetuses, previously some studies suggested a con-
nection and others claimed no significant associa-
tion.5,6,7,8
MATERIALS AND METHODS
This was a retrospective study performed by search-
ing the data of women attending to İstanbul Bilim 
University  Europe  Hospital  for  Down  syndrome 
screening  between  January  2006  and  December 
2010.  Ultrasound  examinations  were  performed 
routinely at 11-13 weeks of gestation. All measure-
ments were carried out by two obstetricians (NG, 
Hİ)  using  the  5-MHz  curvilinear  transabdominal 
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women delivering at our institution were included. 
Exclusion criteria were the presence of incomplete 
information, smoking, known abnormal fetal karyo-
type,  congenital  malformations,  pregnancies  with 
more than one fetus and pregnancies with missing 
information. We did not exclude any case on the ba-
sis of abnormal fetal biometry or birth weight. Last 
menstrual period was recorded and the estimated 
date of delivery was corrected according to the first 
trimester crown-rump length (CRL) measurement. 
All serum analyses were performed at a single site 
and the values were corrected for maternal weight. 
The research project has been approved by the Eth-
ics Committee of our University and it conforms to 
the ethical guidelines of the Declaration of Helsinki.
Maternal serum samples for PAPP-A were as-
sayed with the chemiluminescence UnicelDxl 800 
Beckman  coulter  and  the  results  were  converted 
into multiples of median (MoM). For statistical anal-
ysis PAPP-A levels less than the 5th percentile (≤ 
0,39 MoM) were considered as a risk factor for SGA 
infants. Small for gestational age was defined as 
a birth weight less than the 10th percentile for the 
gestational age at delivery. .
For statistical analysis we used NCSS (Num-
ber Cruncher Statistical System) 2007 and PASS 
(Power Analysis and Sample Size) 2008 statistical 
Software (Utah, USA). Data showing anthropomet-
ric parameters were presented as mean standard 
deviation. For categorical anaysis we used McNe-
mar test. The results were considered statistically 
significant  when  the  p-value  was  calculated  less 
than 0.05 at a confidence interval of 95%.
RESULTS
We included 642 patients in our study. The demo-
graphic features of the patients were shown in Ta-
ble 1. Mean maternal age was 30±4 years (18-42 
years), mean maternal height was 164±6cm (149-
180cm), mean maternal weight before pregnancy 
was 62±10 kg (40-104 kg), mean maternal weight 
at delivery was 77±10kg (54-115 kg), mean mater-
nal weight gain during pregnancy was 15±5 kg (-2 
to +45 kg), mean gestational age at the time of first 
trimester screening test was 12+1 weeks. The sen-
sitivity of PAPP-A was 3,5%, specificity 90%, posi-
tive predictive value 1,6% and negative predictive 
value 95% (Table 2). There was a statistically signif-
icant correlation between PAPP-A and SGA infants 
(p<0,001). Odds Ratio was 0,32 (0,042-2,37).
Table 1. Demographic characteristics of the patients
(n=642) Min-Max Mean ±SD
Age (years) 18-43 30±4
Gravidity (n) 0-7 1,6±1
Parity (n) 0-3 0,3±0,5
Abortus (n) 0-4 0,1±0,4
Maternal weight before
 pregnancy (kg)
40-104 62±10
Maternal weight at
 delivery (kg)
54-115 77±10
Maternal weight gain
 in pregnancy (kg)
-2 to 45 15±5
First trimester screening
 test (weeks)
11+4 to 13+6 12+2
Gestational age at
 delivery (weeks) 34-42 39±1,2
Table 2. The relationship between serum PAPP-A levels 
and birth weight percentile
Birth weight percentile PAPP-A*
< %5 ≥ %5 Total
SGA* 1 (%3,4) 62 (%10,1) 63 (%9,8)
Non-SGA 28 (%96,6) 551 (%89,9) 579 (%90,2)
Total 29 (%4,5) 613 (%95,5) 642 (%100)
p 0,001**
Sensitivity (%) 3,5
Specificity (%) 90
Positive predictive value 1,6
Negative predictive value 95
McNemar Test **p<0,01
PAPP-A: pregnancy associated plasma protein A
SGA: small for gestational age
DISCUSSION
The mechanisms underlying the development of a 
SGA infant are initiated in the first trimester of preg-
nancy,9 but the manifestations cannot be detected 
until the second trimester. The trophoblast-derived 
PAPP-A increases the availability of IGF, which is 
known to regulate fetal growth by enhancing tro-
phoblast invasion to the decidua10 and low levels N. Güdücü ve ark. PAPP-A levels and SGA prediction 187
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of PAPP-A show impaired placental function. Low 
PAPP-A levels were suggested to result in SGA in-
fants by decreasing the availability of nutrients to 
chorionic villi.11 The resulting early-onset abnormal 
placentation leads to a late-onset pregnancy com-
plication.
When  we  use  PAPP-A  as  a  marker  for  the 
detection of SGA infants, only 3% of them could 
be predicted. A previous study where ≤ 0,3 MoM 
was used as a cut-off level, sensitivity was given 
as  5,1%,12  similar  to  our  study. This  prevents  its 
use as a screening test without an adjunctive test. 
The search for finding a marker that could detect 
growth restriction earlier has not been successful 
yet.13 Detection of such a marker may give us the 
advantage of intervention with aspirin to decrease 
the  effects  of  abnormal  placentation.14  Combina-
tion of PAPP-A with second trimester uterine artery 
Doppler findings were shown to increase the pre-
dictive accuracy of first trimester PAPP-A15 when is 
too late for intervention. This can at least provide 
effective monitorization of suspected cases and de-
livery when indicated, such a policy was shown to 
decrease the mortality and morbidity.1
Previously low and high levels of PAPP-A were 
shown to be associated with SGA and LGA infants 
respectively.16 PAPP-A levels below the 5th percen-
tile were shown to be associated with higher rates 
of low birth weight infants.5,17,18 Yet another study 
found no association between decreased PAPP-A 
levels and low birth weight infants.8 The association 
between serum PAPP-A levels and delivery of SGA 
infants was relatively weak in our study. Due its low 
predictive value the use of serum PAPP-A level as a 
primary screening test is limited.
The  association  between  decreased  PAPP-A 
levels  and  smoking  has  been  demonstrated  be-
fore19 and chronic maternal diseases have been as-
sociated with an increased risk of delivering SGA in-
fants,20 therefore we excluded women with chronic 
maternal diseases and smokers instead of making 
an adjustment.
Our study had the disadvantage of using tra-
ditional  growth  centiles,  it  has  been  shown  that 
customized  growth  centiles  based  on  physiologic 
determinants  of  birth  weight  discriminated  consti-
tutionally small babies better from growth-restricted 
babies.21 We also did not take the gender of the in-
fants into consideration.
In conclusion serum PAPP-A level cannot be 
used as a screening test for the determination of 
SGA infants, but it can be taken into consideration 
when  a  first  trimester  Down  syndrome  screening 
test is already presented. Further research to find 
markers that can increase the predictive value of 
PAPP-A are warranted.
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